|
Schirdewan博士的引述的參考文獻:
7 @! A# B# R2 z: }0 d, W. n6 W' c5 _" H1 N: ]4 Y# e9 e
Camm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009. , t: v. S+ Q! L0 M! {
" q1 {9 g4 d- L* B
Daubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008
1 K" K! o7 q/ Z" ]. r8 M9 y! x+ T
. j! _: h% o6 v4 ~ d2 Z1 VRicci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010.
0 n5 {0 H- @ l( ^* I, e+ d1 h4 }4 `6 X! e
關於BIOTRONIK SE & Co. KG' J$ c$ I) {" I. {. m% D C
5 u$ f" \3 Z+ Y* i" {; u; q% D7 DBIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|